Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Practical Statistics for Medical Research.

Sophie Walter, Daniel Altman · Biometrics · 1992 · 11.7K citations

Natural Sciences, Biostatistics, Health Sciences +12

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15